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ABSTRACT
Myelodysplastic syndromes are a group of clonal disorders affecting the hemopoietic stem cells and characterized by peripheral 
cytopenias with normocellular to hypercellular bone marrow and various morphological abnormalities in one or more hemopoietic 
cell lines. MDS carries a high risk of progression to acute myeloid leukemia especially in subtypes with increased myeloblasts. 
Here, we present the case of leukemic transformation in MDSin a 41-year-old male who presented with complaints of generalized 
weakness, loss of appetite for 2 months and fever on and off for 1 week. The patient was diagnosed as MDS-multilineage dysplasia 
after blood examination and bone marrow biopsy but the patient refused for further treatment.
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Myelodysplastic syndromes (MDS) are a group of clonal disorders affecting the hemopoietic stem cells. They are characterized by cytopenia with normocellular 
to hypercellular bone marrow and various morphological 
abnormalities in hemopoietic cell lines. The condition carries 
a high risk of progressionto acute myeloid leukemia (AML) 
especially in subtypes with increased myeloblasts. The incidence 
of the transformation of MDS to AML in India is about 0.5-2%, 
with a median time of 272 days [1]. Many factors have been 
evaluated for individual risk assessment in these patients. Various 
transforming mutations that affect hematopoietic stem cells can 
lead to different patterns of dysregulated signal transduction, 
bringing rise to phenotypic diversity [2].
CASE REPORT
A 41-year-old male presented to our department with complaints 
of generalized weakness, loss of appetite for 2 months and fever 
on and off for 1 week.The patient’s past, family and medical 
histories were non-significant. Physical examination revealed 
severe pallor with no organomegaly. The vitals were stable with a 
blood pressure of 110 /80 mmHg and pulse rate of 68/min. 
Complete blood count showed hemoglobin of 4.5 gm/dl, 
total leucocyte count (TLC) of 3560/mm3 and platelet count 
of 70000/ ul. Differential leucocyte count showed N-42%, 
L-52%, M-5%, E-1% where the percentage of blasts was <1% 
with a mild left shift. Hypolobated neutrophils were seen on 
peripheral blood film examination (Fig. 1). Bone marrow 
aspiration evaluation showed dysplastic features in >10% of the 
erythroid cell (megaloblastic maturation, binucleation, nuclear 
budding), myeloid cells (hypolobation of neutrophils) and 
megakaryocytes (hypolobated and micromegakaryocytic form) 
(Fig. 2). Approximately, 7% of ring sideroblast were seen. Blast 
count was <5%. The patient was diagnosed as myelodysplastic 
syndrome-multilineage dysplasia.
The patient refused further evaluation and treatment. He 
came back to the hospital after one year with acute exacerbation 
of previous complaints. Complete blood count done at this 
time showed lower hemoglobin (2.6gm/dl) with higher 
leucocyte count (30340/mm3) and 33% blasts. Peripheral 
blood picture showed, in addition, hypolobated neutrophils 
and myeloid precursors with pseudo Chediak Higashi granules 
and cytoplasmic vacuolation. The patient again refused further 
evaluation and treatment except for blood transfusion. After 20 
days of discharge, he returned with a TLC of 198670 cells/mm3 
and 76% blasts in the peripheral blood.
DISCUSSION 
Myelodysplastic syndrome (MDS) is a heterogeneous group of 
clonal stem cell disorder with variable disease course varying 
from indolent to rapid progression to AML. Andrew et al found 
a case to be transformed from MDS to AML with monocytic 
differentiation just within 1 month and the patient presented with 
the exacerbation of symptoms [3]. To assess the risk defining 
factors, it is important to understand the mechanism of disease 
progression which is not well established and is complex. 
Accumulation of cytogenetics and molecular aberrations, an 
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imbalance between apoptosis, a proliferation of hematopoietic 
cells, stromal defects and host response are some of the theories 
proposed for the leukemic transformation of MDS.
Class I mutation involved in signal transduction (kit, IDH 
1, NPM1) affecting cellular survival and proliferation are 
implicated in MDS progression to AML [4] while Class II 
mutation (RUNX 1, Tet 2) affect cellular differentiation and 
have a significant role in MDS initiation. Some authors have 
observed a correlation between risk of transformation and 
karyotype complexity in patients with 5 q- abnormality while 
the presence of abnormalities in chromosome 7 carried a high 
risk of disease progression independent of other chromosomal 
abnormalities [5,6].
Gene oncology analysis supports the proposition that apoptosis 
in early MDS leads to ineffective hematopoiesis while increased 
genomic instability due to DNA damage checkpoint disruption 
is seen in MDS with the transformation to AML. In a study, 
a high methylation profile of 10 selected genes was found to be 
an independent predictor of disease progression-free survival. 
A deranged immune response heralded by increased no of T-reg 
cell and decreased expression of the activity of natural killer cell 
receptors is seen in patients with high-risk MDS [7,8]. Morphological 
features related to AML transformation include >5% blasts in 
bone marrow smears, presence of abnormally localized immature 
precursors (ALIP) by immunohistochemistry (IHC), hypercellular 
bone marrow and significant fibrosis in bone marrow biopsies by 
reticulin stain. Abnormal immunophenotype which is associated 
with high-risk is aberrant express in lymphoid associated markers 
(CD4, CD7, CD56), overexpression of CD34, CD36, and Tdt.
CONCLUSION
Many factors including percentage of blasts, infiltration patterns 
of blasts and complex karyotype have been associated with 
greater risk of transformation. The present case did not have 
>1% blasts in peripheral blood or >5% blasts in bone marrow 
at the time of presentation but still progressed to AML.A multi-
step leukemogenesis with an accumulation of cytogenetic and 
molecular aberrations during the course of the disease has been 
proposed in many studies.
REFERENCES
1. Okuyama N, Sperr WR, Kadar K, Bakker S, Szombath G, Handa H, et al. 
Prognosis of acute myeloid leukemia transformed from myelodysplastic 
syndromes: A multicenter retrospective study. Leuk Res. 2013;37:862-7. 
DOI: https://doi.org/10.1016/j.leukres.2013.02.018.
2. Tefferi A, Vardiman JW. Myelodysplastic syndromes. N Engl J Med. 
2009;361:1872-85. DOI: https://doi.org/10.1056/nejmra0902908
3. Pourmoussa A. An Unlikely Rapid Transformation of Myelodysplastic 
Syndrome to Acute Leukemia: A Case Report. The Perm J. 2017;21:16-091.
4. Nolte F, Hofmann WK. Molecular mechanisms involved in the progression 
of myelodysplastic syndrome. Future oncol. 2010;6: 445-55.
5. Mallo M, Cervera J, Schanz J, Such E, García-Manero G, Luño E, et al. Impact 
of adjunct cytogenetic abnormalities for prognostic stratification in patients 
with myelodysplastic syndrome and deletion 5q. Leukemia 2011;2:110-20. 
6. Haase D. Cytogenetic features in myelodysplastic syndromes. Annals of 
Hematol. 2008;87:515-26. 
7. Pellagatti A, Cazzola M, Giagounidis A, Perry J, MalcovatiL, Della Porta 
MG et al. Deregulated gene expression pathways in myelodysplastic 
syndrome hematopoietic stem cells. Leukemia. 2010;24:756-64.
8. Epling-Burnette PK, Bai F, Painter JS, Rollison DE, Salih HR, Krusch 
M, et al. Reduced natural killer (NK) function associated with high-risk 
myelodysplastic syndrome (MDS) and reduced expression of activating NK 
receptors. Blood. 2007;109:4816-24.
Funding: None; Conflict of Interest: None Stated.
How to cite this article: Singh P, Acharya S, Azad S, Thakur B, Kochhar M. 
Leukemic transformation in myelodysplastic syndrome: a case report with 
review of risk factors. Indian J Case Reports. 2019;5(4):386-387. 
Doi: 10.32677/IJCR.2019.v05.i04.031
Figure 2: Bone marrow aspiration:1000X: Hypolobated 
megakaryocytes and micromegakaryocytes.
Figure 1: Peripheral blood film. Leishman stain:1000X. (a) 
hypolobated neutrophils and (b) blasts cells.
